Advertisement

Topics

Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma

06:19 EDT 13 Oct 2018 | Nature Publishing

Original Article: Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma

NEXT ARTICLE

More From BioPortfolio on "Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma"

Advertisement
Quick Search
Advertisement
Advertisement